Skip to main content
SpringerLink
Log in

Imatinib and CAR T cell therapy enable sustained response in a young patient with refractory RCSD1-ABL1-positive acute lymphoblastic leukemia

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Mustjoki S, Hernesniemi S, Rauhala A et al (2009) A novel dasatinib-sensitive RCSD1-ABL1 fusion transcript in chemotherapy-refractory adult pre-B lymphoblastic leukemia with t(1;9)(q24;q34). Haematologica 94(10):1469–1471

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  2. Peyam S, Bhatia P, Singh M et al (2022) Clinico-hematological and Outcome Profile of Pediatric B-other-ALL and BCR::ABL1-like pre-B-ALL: An Integrated Genomic Study From North India. Clin Lymphoma Myeloma Leuk 22(8):e667–e679

    Article  PubMed  CAS  Google Scholar 

  3. Frech M, Jehn LB, Stabla K et al (2017) Dasatinib and allogeneic stem cell transplantation enable sustained response in an elderly patient with RCSD1-ABL1-positive acute lymphoblastic leukemia. Haematologica 102(4):e160–e162

    Article  PubMed  PubMed Central  Google Scholar 

  4. Perwein T, Strehl S, Konig M et al (2016) Imatinib-induced long-term remission in a relapsed RCSD1-ABL1-positive acute lymphoblastic leukemia. Haematologica 101(8):e332–e335

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This work was supported by the National Natural Science Foundation of China (grant number 81700125); Scientific Research Project of Hunan Provincial Health Commission (202203045312)

Author information

Authors and Affiliations

  1. Department of Hematology, The Second Xiangya Hospital, Central South University, Renminzhong Road 139, Changsha, 410011, Hunan Province, China

    Yajuan Cui & Hongling Peng

Authors
  1. Yajuan Cui
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hongling Peng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hongling Peng.

Ethics declarations

Ethics approval and consent to participate

A written informed consent was obtained from the patient for the publication.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cui, Y., Peng, H. Imatinib and CAR T cell therapy enable sustained response in a young patient with refractory RCSD1-ABL1-positive acute lymphoblastic leukemia. Ann Hematol 103, 361–362 (2024). https://doi.org/10.1007/s00277-023-05489-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-023-05489-8

Search

Navigation